Every tumor is different
with its own ever-changing unique genomic profile
We target the source
developing new targeted therapies for cancer patients
with an activated Notch pathway
We target cancer at its source
Dysregulation of the Notch pathway may lead to carcinogenic activity. Our investigational new drug, AL101, was developed to inhibit the Notch pathway in cancer.
We target uniqueness
As precision oncology and diagnostics evolve, we can start to target the underlying mechanisms for cancers, especially for rare cancers where no approved therapies exist.
